Atypical age of onset of the small bowel adenocarcinoma – case report
DOI:
https://doi.org/10.12775/JEHS.2022.12.10.039Keywords
Small bowel adenocarcinoma, ileus, covid-19Abstract
Background: Small bowel adenocarcinoma is a rare malignant tumor, with the typical age of diagnosis being 60 years old. In the field of risk factors, we can distinguish, between genetic disorders, inflammatory bowel diseases, smoking, and alcohol abuse. Guidelines for the screening methods are very wide, hence it may be difficult to make the right diagnosis at the early stages of cancer. Additional difficulties can be caused by similarities to inflammatory processes in the gastrointestinal tract.
Case report: We present a case of a 22-year-old male patient, with the symptoms of weight loss, stool retention, abdominal pain, and vomiting. The patient was initially misdiagnosed with inflammatory bowel disease and received the first dose of anti-inflammatory treatment. At that point, the diagnostic process and the workflow of medical care were delayed due to the COVID-19 pandemic. After receiving the x-ray and computed tomography, the obstruction of the ileum was found, and an urgent operation was performed. Tissue samples obtained during surgery revealed the proper diagnosis, a low-differentiated adenocarcinoma (G3) of the small intestine, stage T4Nx.
Conclusion: Taking into consideration the patient’s condition, age, and symptoms, we should always think about the probable malignant process. Inflammatory diseases are known for increasing cancer risk and should always be the indication of this disease. The age of onset of the disease is very unusual, however, we must be aware of such cases in our clinical practice.
References
Barsouk A, Rawla P, Barsouk A, Thandra KC. Epidemiology of Cancers of the Small Intestine: Trends, Risk Factors, and Prevention. Medical Sciences. 2019; 7(3):46. https://doi.org/10.3390/medsci7030046
Cordova-Delgado M, Pizarro G, Pinto MP, Herrera ME, Garrido M. Case Report: Molecular Features and Treatment Options for Small Bowel Adenocarcinoma. Front Oncol. 2021;11:593561. Published 2021 Mar 10. doi:10.3389/fonc.2021.593561
Aparicio T, Zaanan A, Mary F, Afchain P, Manfredi S, Evans TR. Small Bowel Adenocarcinoma. Gastroenterol Clin North Am. 2016;45(3):447-457. doi:10.1016/j.gtc.2016.04.004
Bilimoria KY, Bentrem DJ, Wayne JD, et al. Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg 2009;249:63–71. doi: 10.1097/SLA.0b013e31818e4641.
Jovanovic I, Fry LC, Mönkemüller K. Small-bowel adenocarcinoma. Clin Gastroenterol Hepatol. 2011;9(3):A28. doi:10.1016/j.cgh.2010.11.003
Benson AB, Venook AP, Al-Hawary MM, et al. Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17(9):1109-1133. doi:10.6004/jnccn.2019.0043
Li J, Wang Z, Liu N i wsp. Small bowel adenocarcinoma of the jejunum: a case report and literature review. World J Surg Oncol 2016; 14: 177. doi: 10.1186/s12957-016-0932-3.
Giuffrida P, Vanoli A, Arpa G, et al. Small Bowel Carcinomas Associated with Immune-Mediated Intestinal Disorders: The Current Knowledge. Cancers (Basel). 2018;11(1):31. Published 2018 Dec 29. doi:10.3390/cancers11010031
Bojesen RD, Riis LB, Høgdall E, Nielsen OH, Jess T. Inflammatory Bowel Disease and Small Bowel Cancer Risk, Clinical Characteristics, and Histopathology: A Population-Based Study. Clin Gastroenterol Hepatol. 2017;15(12):1900-1907.e2. doi:10.1016/j.cgh.2017.06.051
Lewis JD, Deren JJ, Lichtenstein GR. Cancer risk in patients with inflammatory bowel disease. Gastroenterol Clin North Am. 1999;28(2):459-x. doi:10.1016/s0889-8553(05)70065-0
Palascak-Juif V, Bouvier AM, Cosnes J, et al. Small bowel adenocarcinoma in patients with Crohn's disease compared with small bowel adenocarcinoma de novo. Inflamm Bowel Dis. 2005;11(9):828-832. doi:10.1097/01.mib.0000179211.03650.b6
Schrock AB, Devoe CE, McWilliams R, et al. Genomic Profiling of Small-Bowel Adenocarcinoma. JAMA Oncol. 2017;3(11):1546–1553. doi:10.1001/jamaoncol.2017.1051
Zaanan A, Costes L, Gauthier M, et al. Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study. Ann Oncol. 2010;21(9):1786-1793. doi:10.1093/annonc/mdq038
Aparicio T, Zaanan A, Svrcek M, et al. Small bowel adenocarcinoma: epidemiology, risk factors, diagnosis and treatment. Dig Liver Dis. 2014;46(2):97-104. doi:10.1016/j.dld.2013.04.013
Gore RM, Mehta UK, Berlin JW, Rao V, Newmark GM. Diagnosis and staging of small bowel tumours. Cancer Imaging. 2006;6(1):209-212. Published 2006 Dec 29. doi:10.1102/1470-7330.2006.0031
Mama N, Ben Slama A, Arifa N, et al. Duodenal adenocarcinoma presenting as a mass with aneurismal dilatation. Clin Imaging. 2014;38(2):205-207. doi:10.1016/j.clinimag.2013.11.004
Barat M, Dohan A, Dautry R, et al. Mass-forming lesions of the duodenum: A pictorial review. Diagn Interv Imaging. 2017;98(10):663-675. doi:10.1016/j.diii.2017.01.004
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Katarzyna Szklener, Maria Maciąg, Aleksandra Marczak, Mikołaj Margas, Sławomir Mańdziuk
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 318
Number of citations: 0